Metformin Suppresses MHC-Restricted Antigen Presentation by Inhibiting Co-Stimulatory Factors and MHC Molecules in APCs.
- Author:
Seulmee SHIN
1
;
Bobae HYUN
;
Aeri LEE
;
Hyunseok KONG
;
Shinha HAN
;
Chong Kil LEE
;
Nam Joo HA
;
Kyungjae KIM
Author Information
1. College of Pharmacy, Sahmyook University, Seoul 139-742, Republic of Korea. kimkj@syu.ac.kr
- Publication Type:Original Article
- Keywords:
Metformin;
MHC-restricted antigen presentation;
Antigen-presenting cells
- MeSH:
Animals;
Antigen Presentation*;
Antigen-Presenting Cells;
Immune System;
Immunotherapy;
Metformin*;
Mice;
Ovum
- From:Biomolecules & Therapeutics
2013;21(1):35-41
- CountryRepublic of Korea
- Language:English
-
Abstract:
Metformin is widely used for T2D therapy but its cellular mechanism of action is undefined. Recent studies on the mechanism of metformin in T2D have demonstrated involvement of the immune system. Current immunotherapies focus on the potential of immunomodulatory strategies for the treatment of T2D. In this study, we examined the effects of metformin on the antigen-presenting function of antigen-presenting cells (APCs). Metformin decreased both MHC class I and class II-restricted presentation of OVA and suppressed the expression of both MHC molecules and co-stimulatory factors such as CD54, CD80, and CD86 in DCs, but did not affect the phagocytic activity toward exogenous OVA. The class II-restricted OVA presentation-regulating activity of metformin was also confirmed using mice that had been injected with metformin followed by soluble OVA. These results provide an understanding of the mechanisms of the T cell response-regulating activity of metformin through the inhibition of MHC-restricted antigen presentation in relation to its actions on APCs.
